Company Encyclopedia
View More
name
Eupraxia Pharmaceuticals
EPRX.US
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. The company’s proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. Its lead product candidates include EP-104IAR, which is in Phase III clinical trial for the treatment of unmet medical needs and pain relief for knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of other inflammatory joint conditions, benign structures of the esophagus, and epidural delivery. The company was formerly known as Plaza Capital Partners Inc.
1.875 T
EPRX.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Cantor Fitzgerald Reaffirms Their Buy Rating on Eupraxia Pharmaceuticals (EPRX)

    Cantor Fitzgerald's Kristen Kluska reaffirms a Buy rating on Eupraxia Pharmaceuticals with a price target of $11.00. Kluska, a 5-star analyst with a 34.3% average return, focuses on the Healthcare sector. The analyst consensus for Eupraxia is a Strong Buy with an average price target of C$14.52.

    Tip Ranks·
    US
    EPRX
    0.00%
    Tip Ranks·
    US
    EPRX
    0.00%

    Eupraxia Reports Durable 52-Week Symptom Relief With EP-104GI in Eosinophilic Esophagitis Trial

    Eupraxia Pharmaceuticals Inc. announced 52-week follow-up data from its Phase 1b/2a RESOLVE trial for EP-104GI in treating eosinophilic esophagitis. In Cohort 6, all three patients maintained clinical benefit, with two in clinical remission. At week 24, 79% of patients across Cohorts 4-8 were in remission, with a 69% average SDI score reduction. No serious adverse events were reported. The data was presented at the American College of Gastroenterology Annual Scientific Meeting.

    Reuters·
    US
    EPRX
    0.00%
    Reuters·
    US
    EPRX
    0.00%

    Eupraxia Pharmaceuticals: Buy Rating Backed by Strong Pipeline Advancements and Robust Financial Position

    Analyst Brandon Folkes from H.C. Wainwright has reiterated a Buy rating on Eupraxia Pharmaceuticals, maintaining a price target of $12.00. This rating is supported by significant advancements in the company's pipeline, particularly in the EP-104GI program and the Phase 2b RESOLVE trial, which has shown promising results. Eupraxia's strong financial position, with a cash runway until 2028, allows for continued development. The expansion of the trial is expected to enhance its statistical power, further supporting the Buy rating.

    Tip Ranks·
    US
    EPRX
    0.00%
    Tip Ranks·
    US
    EPRX
    0.00%

    Eupraxia Pharmaceuticals Inc. Releases MD&A Report for Q3 2025

    Eupraxia Pharmaceuticals Inc. has released its MD&A report for Q3 2025, detailing its business strategies and objectives, particularly for the development of EP-104IAR. The company is exploring funding alternatives and partnerships to support its operations, including research and commercialization efforts. Updates on operating expenses, capital expenditures, and projected revenues are provided, along with a focus on maintaining competitive advantages and pursuing market opportunities in drug development.

    Reuters·
    US
    EPRX
    0.00%
    Reuters·
    US
    EPRX
    0.00%

    Eupraxia Pharmaceuticals Reports Third Quarter 2025 Financial Results

    Durable symptom and tissue responses observed out to 52 weeks following a single treatment with EP-104GI Enrollment continues in Phase 2b portion of the RESOLVE Trial, with topline data expected by Q3 2026 Cash runway to fund pipeline development and operations into the first half of 2028

    GlobeNewswire·
    US
    EPRX
    0.00%
    GlobeNewswire·
    US
    EPRX
    0.00%